CLINICAL_TRIALS
trial_result
· 2017-03-30
Clinical Trial Update: An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer [Phase 2]
Summary
Phase 2 trial of MORAb-003 (farletuzumab) in platinum-resistant or refractory relapsed ovarian cancer was terminated, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Morphotek | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-30